Aptinyx : Phase 2b Study Of NYX-2925 In Fibromyalgia Fails To Meet Main Goal

(RTTNews) - Aptinyx Inc. (APTX) said that a phase 2b study of NYX-2925 in Fibromyalgia did not achieve statistically significant separation from placebo on the study's primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale or NRS during week 12.

According to the company, the phase 2b fibromyalgia study was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of NYX-2925 in approximately 300 patients with fibromyalgia. Eligible patients were randomized to receive oral doses of NYX-2925 50 mg, NYX-2925 100 mg, or placebo once daily over the treatment period.

The primary endpoint in the study was the change from baseline in average daily pain as reported on the zero-to-ten NRS during week 12 of the study.

Statistically significant separation from placebo was not observed on the primary endpoint of the study with either dose level of NYX-2925. Patients receiving NYX-2925 at both dose levels showed a trend toward clinically meaningful improvement in pain, as well as in some secondary endpoints, versus placebo by week 4. However, by week 12, the placebo group had improved such that, although NYX-2925 remained numerically better, the separation was not clinically meaningful.

Across both dose levels, NYX-2925 was well tolerated in the study, with no concerning safety issues observed.

APTX closed Thursday regular trading at $0.60, down $0.09 or 13.03%. In Friday pre-market trade, the stock was gaining at $0.03 or 5.00%.

For More Such Health News, visit rttnews.com